metaPreg - Amlodipine (versus unexposed) during pregnancy

Amlodipine (versus unexposed)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.42 [0.69, 2.93]	0%	3 studies	119	124	not evaluable	ROB	-
Major congenital malformations	1.46 [0.68, 3.15]	0%	3 studies	99	124	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.01 [0.67, 6.00]	89%	3 studies	105	169	not evaluable	ROB	-
Low birth weight (< 2500g)	1.41 [0.23, 8.44]	95%	2 studies	61	135	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	2.82 [2.35, 3.38]	-	1 study		221	not evaluable	ROB	5.09 [4.13; .]
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low Apgar score (< 7) (NOS)	1.95 [1.55, 2.46]	-	1 study		88	not evaluable	ROB	3.31 [2.47; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study